Pfizer stock (PFE: NYSE) surged on Tuesday after the company delivered stronger-than-expected second-quarter results and lifted its profit outlook for the year.
Revenue climbed 10% to $14.7 billion, topping Wall Street forecasts and offering a sign that Pfizer’s core business is stabilising following a post-COVID slowdown.
Off the back of those numbers, the company raised its 2025 earnings guidance. Adjusted EPS is now expected to land between $2.90 and $3.10, up from the previous forecast.
That’s not a massive leap, but it does show that cost controls and restructuring efforts may be starting to pay off.
The new midpoint of $3.00 per share is still slightly below analyst consensus, but the upward revision was enough to give the stock a lift.
Following the company’s release of impressive quarterly results and a bullish profit outlook for the full year, Pfizer’s stock has gained significant traction.
This positive momentum reflects the company’s effective cost-cutting measures and strategic focus on innovation, which together set the stage for sustained growth and investor confidence amid an evolving healthcare landscape.
Pfizer stock: What’s behind improved outlook
Pfizer is sticking with its full-year revenue outlook, projecting 2025 sales to land between $61 billion and $64 billion.
The guidance comes as the drugmaker posts its first stretch of year-over-year revenue growth since the height of its pandemic vaccine sales.
CEO Dr. Albert Bourla noted ongoing progress in Pfizer’s research pipeline and margin expansion, underscoring the company’s focus on launching new therapies and delivering long-term value to investors.
A big part of Pfizer’s improved earnings outlook comes down to cost discipline. The company already reached $4 billion in net savings by the end of 2024 and expects to trim another $500 million this year through efficiency efforts and streamlining manufacturing.
Those savings have not only supported earnings growth but also freed up cash to invest back into Pfizer’s pipeline, an important move as the company faces patent cliffs and growing competition.
Renewed investor confidence
Pfizer stock jumped over 3% in pre-market trading after the company posted solid Q2 results and lifted its profit outlook for the year. The stronger numbers seem to have renewed some confidence in the company’s direction.
There’s clearly optimism around the cost-cutting progress and the way Pfizer is handling its post-COVID reset.
At the same time, people are paying attention to the pipeline, new products, better margins, and how the company plans to grow beyond one-off vaccine revenue.
That said, it’s not all smooth sailing. Execution still matters. Cost savings are great on paper, but they need to show up consistently.
And while the long-term outlook is better now, investors will want to see proof that the strategy actually delivers results.
The post Pfizer stock pops as big pharma giant delivers post-COVID comeback appeared first on Invezz